Gene transfer in ovarian cancer cells

A comparison between retroviral and lentiviral vectors

Stefano Indraccolo, Walter Habeler, Veronica Tisato, Laura Stievano, Erich Piovan, Valeria Tosello, Giovanni Esposito, Ralf Wagner, Klaus Uberla, Luigi Chieco-Bianchi, Alberto Amadori

Research output: Contribution to journalArticle

54 Citations (Scopus)

Abstract

Local gene therapy could be a therapeutic option for ovarian carcinoma, a life-threatening malignancy, because of disease containment within the peritoneal cavity in most patients. Lentiviral vectors, which are potentially capable of stable transgene expression, may be useful to vehicle therapeutic molecules requiring long-term production in these tumors. To investigate this concept, we used lentiviral vectors to deliver the enhanced green fluorescent protein (EGFP) gene to ovarian cancer cells. Their efficiency of gene transfer was compared with that of a retroviral vector carrying the same envelope. In vitro, both vectors infected ovarian cancer cells with comparable efficiency under standard culture conditions; however, the lentiviral vector was much more efficient in transducing growth-arrested cells when compared with the retroviral vector. Gene transfer was fully neutralized by an anti-VSV-G antibody, and in vitro stability was similar. In vivo, the lentiviral vector delivered the transgene 10-fold more efficiently to ovarian cancer cells growing i.p. in SCID mice, as evaluated by real-time PCR analysis of the tumors. Confocal microscopy analysis of tumor sections showed a dramatic difference at the level of transgene expression, because abundant EGFP+ cells were detected only in mice receiving the lentiviral vector. Quantitative analysis by flow cytometry confirmed this and indicated 0.05 and 5.6% EGFP+ tumor cells after administration of the retroviral and lentiviral vector, respectively. Injection of ex vivo transduced tumor cells, sorted for EGFP expression, indicated that the lentiviral vector was considerably more resistant to in vivo silencing in comparison with the retroviral vector. Finally, multiple administrations of a murine IFN-α1-lentiviral vector to ovarian carcinoma-bearing mice significantly prolonged the animals' survival, indicating the therapeutic efficacy of this approach. These findings indicate that lentiviral vectors deserve attention in the design of future gene therapy approaches to ovarian cancer aimed at achieving long-term expression of therapeutic genes.

Original languageEnglish
Pages (from-to)6099-6107
Number of pages9
JournalCancer Research
Volume62
Issue number21
Publication statusPublished - Nov 1 2002

Fingerprint

Ovarian Neoplasms
Genes
Transgenes
Neoplasms
Genetic Therapy
Carcinoma
SCID Mice
Peritoneal Cavity
Therapeutics
Confocal Microscopy
Real-Time Polymerase Chain Reaction
Flow Cytometry
Gene Expression
Injections
enhanced green fluorescent protein
Antibodies
Growth

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Gene transfer in ovarian cancer cells : A comparison between retroviral and lentiviral vectors. / Indraccolo, Stefano; Habeler, Walter; Tisato, Veronica; Stievano, Laura; Piovan, Erich; Tosello, Valeria; Esposito, Giovanni; Wagner, Ralf; Uberla, Klaus; Chieco-Bianchi, Luigi; Amadori, Alberto.

In: Cancer Research, Vol. 62, No. 21, 01.11.2002, p. 6099-6107.

Research output: Contribution to journalArticle

Indraccolo, S, Habeler, W, Tisato, V, Stievano, L, Piovan, E, Tosello, V, Esposito, G, Wagner, R, Uberla, K, Chieco-Bianchi, L & Amadori, A 2002, 'Gene transfer in ovarian cancer cells: A comparison between retroviral and lentiviral vectors', Cancer Research, vol. 62, no. 21, pp. 6099-6107.
Indraccolo, Stefano ; Habeler, Walter ; Tisato, Veronica ; Stievano, Laura ; Piovan, Erich ; Tosello, Valeria ; Esposito, Giovanni ; Wagner, Ralf ; Uberla, Klaus ; Chieco-Bianchi, Luigi ; Amadori, Alberto. / Gene transfer in ovarian cancer cells : A comparison between retroviral and lentiviral vectors. In: Cancer Research. 2002 ; Vol. 62, No. 21. pp. 6099-6107.
@article{80922f2ddb764ccea775b9cf41fdb508,
title = "Gene transfer in ovarian cancer cells: A comparison between retroviral and lentiviral vectors",
abstract = "Local gene therapy could be a therapeutic option for ovarian carcinoma, a life-threatening malignancy, because of disease containment within the peritoneal cavity in most patients. Lentiviral vectors, which are potentially capable of stable transgene expression, may be useful to vehicle therapeutic molecules requiring long-term production in these tumors. To investigate this concept, we used lentiviral vectors to deliver the enhanced green fluorescent protein (EGFP) gene to ovarian cancer cells. Their efficiency of gene transfer was compared with that of a retroviral vector carrying the same envelope. In vitro, both vectors infected ovarian cancer cells with comparable efficiency under standard culture conditions; however, the lentiviral vector was much more efficient in transducing growth-arrested cells when compared with the retroviral vector. Gene transfer was fully neutralized by an anti-VSV-G antibody, and in vitro stability was similar. In vivo, the lentiviral vector delivered the transgene 10-fold more efficiently to ovarian cancer cells growing i.p. in SCID mice, as evaluated by real-time PCR analysis of the tumors. Confocal microscopy analysis of tumor sections showed a dramatic difference at the level of transgene expression, because abundant EGFP+ cells were detected only in mice receiving the lentiviral vector. Quantitative analysis by flow cytometry confirmed this and indicated 0.05 and 5.6{\%} EGFP+ tumor cells after administration of the retroviral and lentiviral vector, respectively. Injection of ex vivo transduced tumor cells, sorted for EGFP expression, indicated that the lentiviral vector was considerably more resistant to in vivo silencing in comparison with the retroviral vector. Finally, multiple administrations of a murine IFN-α1-lentiviral vector to ovarian carcinoma-bearing mice significantly prolonged the animals' survival, indicating the therapeutic efficacy of this approach. These findings indicate that lentiviral vectors deserve attention in the design of future gene therapy approaches to ovarian cancer aimed at achieving long-term expression of therapeutic genes.",
author = "Stefano Indraccolo and Walter Habeler and Veronica Tisato and Laura Stievano and Erich Piovan and Valeria Tosello and Giovanni Esposito and Ralf Wagner and Klaus Uberla and Luigi Chieco-Bianchi and Alberto Amadori",
year = "2002",
month = "11",
day = "1",
language = "English",
volume = "62",
pages = "6099--6107",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "21",

}

TY - JOUR

T1 - Gene transfer in ovarian cancer cells

T2 - A comparison between retroviral and lentiviral vectors

AU - Indraccolo, Stefano

AU - Habeler, Walter

AU - Tisato, Veronica

AU - Stievano, Laura

AU - Piovan, Erich

AU - Tosello, Valeria

AU - Esposito, Giovanni

AU - Wagner, Ralf

AU - Uberla, Klaus

AU - Chieco-Bianchi, Luigi

AU - Amadori, Alberto

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Local gene therapy could be a therapeutic option for ovarian carcinoma, a life-threatening malignancy, because of disease containment within the peritoneal cavity in most patients. Lentiviral vectors, which are potentially capable of stable transgene expression, may be useful to vehicle therapeutic molecules requiring long-term production in these tumors. To investigate this concept, we used lentiviral vectors to deliver the enhanced green fluorescent protein (EGFP) gene to ovarian cancer cells. Their efficiency of gene transfer was compared with that of a retroviral vector carrying the same envelope. In vitro, both vectors infected ovarian cancer cells with comparable efficiency under standard culture conditions; however, the lentiviral vector was much more efficient in transducing growth-arrested cells when compared with the retroviral vector. Gene transfer was fully neutralized by an anti-VSV-G antibody, and in vitro stability was similar. In vivo, the lentiviral vector delivered the transgene 10-fold more efficiently to ovarian cancer cells growing i.p. in SCID mice, as evaluated by real-time PCR analysis of the tumors. Confocal microscopy analysis of tumor sections showed a dramatic difference at the level of transgene expression, because abundant EGFP+ cells were detected only in mice receiving the lentiviral vector. Quantitative analysis by flow cytometry confirmed this and indicated 0.05 and 5.6% EGFP+ tumor cells after administration of the retroviral and lentiviral vector, respectively. Injection of ex vivo transduced tumor cells, sorted for EGFP expression, indicated that the lentiviral vector was considerably more resistant to in vivo silencing in comparison with the retroviral vector. Finally, multiple administrations of a murine IFN-α1-lentiviral vector to ovarian carcinoma-bearing mice significantly prolonged the animals' survival, indicating the therapeutic efficacy of this approach. These findings indicate that lentiviral vectors deserve attention in the design of future gene therapy approaches to ovarian cancer aimed at achieving long-term expression of therapeutic genes.

AB - Local gene therapy could be a therapeutic option for ovarian carcinoma, a life-threatening malignancy, because of disease containment within the peritoneal cavity in most patients. Lentiviral vectors, which are potentially capable of stable transgene expression, may be useful to vehicle therapeutic molecules requiring long-term production in these tumors. To investigate this concept, we used lentiviral vectors to deliver the enhanced green fluorescent protein (EGFP) gene to ovarian cancer cells. Their efficiency of gene transfer was compared with that of a retroviral vector carrying the same envelope. In vitro, both vectors infected ovarian cancer cells with comparable efficiency under standard culture conditions; however, the lentiviral vector was much more efficient in transducing growth-arrested cells when compared with the retroviral vector. Gene transfer was fully neutralized by an anti-VSV-G antibody, and in vitro stability was similar. In vivo, the lentiviral vector delivered the transgene 10-fold more efficiently to ovarian cancer cells growing i.p. in SCID mice, as evaluated by real-time PCR analysis of the tumors. Confocal microscopy analysis of tumor sections showed a dramatic difference at the level of transgene expression, because abundant EGFP+ cells were detected only in mice receiving the lentiviral vector. Quantitative analysis by flow cytometry confirmed this and indicated 0.05 and 5.6% EGFP+ tumor cells after administration of the retroviral and lentiviral vector, respectively. Injection of ex vivo transduced tumor cells, sorted for EGFP expression, indicated that the lentiviral vector was considerably more resistant to in vivo silencing in comparison with the retroviral vector. Finally, multiple administrations of a murine IFN-α1-lentiviral vector to ovarian carcinoma-bearing mice significantly prolonged the animals' survival, indicating the therapeutic efficacy of this approach. These findings indicate that lentiviral vectors deserve attention in the design of future gene therapy approaches to ovarian cancer aimed at achieving long-term expression of therapeutic genes.

UR - http://www.scopus.com/inward/record.url?scp=0036827965&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036827965&partnerID=8YFLogxK

M3 - Article

VL - 62

SP - 6099

EP - 6107

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 21

ER -